GlassScriptPhysician profile
Janet Luu
NPI 1427624063
$2,330.12
in general payments reported to CMS, 2019-2025
14 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $524 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330 · Grant: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.12 |
| Grant | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,161.75 | 2024-2025 | |
| Grifols USA, LLC | $256.37 | 2024-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $230.40 | 2024-2025 | Takhzyro, Cuvitru, Eohilia |
| Astrazeneca Pharmaceuticals LP | $203.07 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $148.21 | 2025 | Dupixent |
| Glaxosmithkline, LLC. | $135.33 | 2024-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $40.93 | 2024-2025 | Zerbaxa, Dificid |
| Siemens Medical Solutions USA, INC. | $29.76 | 2025 | Immulite 1000 Immunoassay System |
| Novartis Pharmaceuticals Corporation | $29.15 | 2025 | |
| Medtronic, INC. | $22.32 | 2025 | Symplicity G3 |
| Blueprint Medicines Corporation | $20.49 | 2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $19.91 | 2025 | Neffy |
| Csl Behring | $17.09 | 2024 | Hizentra |
| Lilly USA, LLC | $15.34 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.